Péptidos y Proteínas
Los péptidos son cadenas cortas de aminoácidos unidas por enlaces peptídicos, mientras que las proteínas son cadenas más largas y complejas de aminoácidos que pueden adoptar estructuras tridimensionales funcionales. Ambos tipos de compuestos son esenciales para diversas funciones biológicas, como la catalización de reacciones (enzimas), la defensa inmunológica (anticuerpos) y la señalización celular. Las proteínas tienen una estructura jerárquica, que incluye la secuencia de aminoácidos, la estructura secundaria, terciaria y cuaternaria. Los péptidos se utilizan en terapias farmacológicas y cosméticas por sus propiedades biológicas específicas, como en el tratamiento de enfermedades metabólicas o la mejora de la regeneración celular. Las proteínas, por su parte, tienen aplicaciones en biotecnología, nutrición y medicina regenerativa.
En CymitQuimica ofrecemos péptidos y proteínas de alta pureza para investigación en biotecnología y aplicaciones terapéuticas.
Se han encontrado 3126 productos de "Péptidos y Proteínas"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Carfilzomib (2R,4S)-Diol
CAS:Producto controlado<p>Applications Carfilzomib (2R,4S)-Diol is a derivative of Carflizomib (C183460), a second-generation proteasome inhibitor that is used as a treatment in relapsed and refractory multiple myeloma.<br>References Fostier, K., et al.: Oncotargets. Therap., 5, 237 (2012); Geurink, P.P., et al.: J. Med. Chem., 56, 1262 (2013); McCormack, P.L., et al.: Drugs., 72, 2023 (2012);<br></p>Fórmula:C40H59N5O8Forma y color:NeatPeso molecular:737.93Carfilzomib (2R,4R)-Diol
Producto controlado<p>Applications Carfilzomib (2R,4R)-Diol is a derivative of Carflizomib (C183460), a second-generation proteasome inhibitor that is used as a treatment in relapsed and refractory multiple myeloma.<br>References Fostier, K., et al.: Oncotargets. Therap., 5, 237 (2012); Geurink, P.P., et al.: J. Med. Chem., 56, 1262 (2013); McCormack, P.L., et al.: Drugs., 72, 2023 (2012);<br></p>Fórmula:C40H59N5O8Forma y color:NeatPeso molecular:737.93Methyltetrazine-Amine
CAS:<p>Methyltetrazine-Amine is a methyl-substituted tetrazine amine used in the synthesis of PROTAC molecules.</p>Fórmula:C10H11N5Pureza:97.59%Forma y color:Pink SolidPeso molecular:201.23Lisinopril Cyclohexyl Analogue
CAS:Producto controlado<p>Impurity Lisinopril EP Impurity F<br>Applications Lisinopril Cyclohexyl Analogue (Lisinopril EP Impurity F) is a Lisinopril (L468985) impurity.<br>References Paraskevas, G., et al.: J. Pharm. Biomed. Anal., 29, 865 (2002),<br></p>Fórmula:C21H37N3O5Forma y color:NeatPeso molecular:411.54Tabimorelin
CAS:Producto controlado<p>Applications NN703 (Tabimorelin) is an orally active growth hormone (GH) secretagogue intended for use as an alternative to daily injections of GH. In vitro studies in human liver microsomes have indicated that NN703 is a mechanism-based inhibitor of CYP3A4.<br>References Fabre, G., et al.: Biochem. Pharmacol., 37, 4389 (1988), Thummel, K., et al.: Clin. Pharmacol. Ther., 59, 491 (1996), Yu, D., et al.: J. Clin. Pharmacol., 39, 1203 (1999),<br></p>Fórmula:C32H40N4O3Forma y color:NeatPeso molecular:528.68Carbetocin
CAS:<p>Applications An obstetric drug used to control postpartum hemorrhaging.<br>References Sanz-Nebot, V., et al.: Anal. Bioanal. Chem., 377, 306 (2003), Gimpl, G., et al.: Eur. J. Pharmacol., 510, 9 (2005), Handler, J., et al.: Theriogenol., 66, 1397 (2006), Klenerova, V., et al.: J. Physiol. Pharmacol., 60, 57 (2009),<br></p>Fórmula:C45H69N11O12SForma y color:NeatPeso molecular:988.16Lisinopril (S,S,R)-Diketopiperazine (~90%)
CAS:<p>Impurity Lisinopril EP Impurity D<br>Stability Hygroscopic<br>Applications Lisinopril (S,S,R)-Diketopiperazine (Lisinopril EP Impurity D) is an impurity of Lisinopril (L468985), an orally active angiotensin-converting enzyme (ACE) inhibitor (1).<br>References 1. Goa, K. et al.: Drugs. 1996 Oct;52(4):564-88.<br></p>Fórmula:C21H29N3O4Pureza:~90%Forma y color:White To Off-WhitePeso molecular:387.47Bivalirudin Plus-Gly Fragment Trifluoroacetic Acid Salt (Impurity)
<p>Applications Impurity of Bivalirudin, a direct thrombin inhibitor acting as an anticoagulant through inhibition of the enzyme thrombin.<br>References Bertrand, O. et al.: Am. J. Cardio., 110, 599 (2012); Patti, G. et al.: Am. J. Cardio., 110, 478 (2012);<br></p>Fórmula:C100H141N25O34•xC2HF3O2Forma y color:NeatPeso molecular:2237.34 + x(114.02)N-Nitroso-D-proline
CAS:Producto controlado<p>Applications A nitrosoamino acid with oncogenic activity. The LD50 of a single ip dose given to Swiss-Webster mice is 203 +/- 22 mg / kg.<br>References Nagasawa, H.T., et al.: J. Med. Chem., 16 (5), 583-585 (1973)<br></p>Fórmula:C5H8N2O3Forma y color:NeatPeso molecular:144.13Semaglutide Impurity 54 (D-Ala 18)
<p>D-Ala(18)-Semaglutide is a semaglutide impurity. The amino acid at position 18 has been replaced by the D-form of the amino acid D-alanine (D-Ala). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molSemaglutide Impurity 59
<p>D-Arg(28)-Semaglutide is a semaglutide impurity. The amino acid at position 28 has been replaced by the D-form of the amino acid D-arginine (D-Arg). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molD-Val(10)-Semaglutide
<p>D-Val(10)-Semaglutide is a semaglutide impurity. The amino acid at position 10 has been replaced by the D-form of the amino acid D-valine (D-Val). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molD-His(1)-Semaglutide
<p>D-His(1)-Semaglutide is a semaglutide impurity. The amino acid at position 1 has been replaced by the D-form of the amino acid D-histidine (D-His). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molD-Asp(9)-Semaglutide
<p>D-Asp(9)-Semaglutide is a semaglutide impurity. The amino acid at position 9 has been replaced by the D-form of the amino acid D-aspartic acid (D-Asp). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molSemaglutide Impurity 29 (β-Asp-9)
<p>Beta-Asp-(9)-Semaglutide is a semaglutide impurity. The amino acid at position 9 has been replaced by the beta-aspartic acid (also known as isoaspartic, isoAsp, β-Asp or beta-Asp). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molLinear Semaglutide
<p>Linear semaglutide, or simply L-Sema, is the semaglutide compound without the lipid side chain modification. It is essentially a linear version of the peptide.</p>Fórmula:C152H230N42O47Peso molecular:3,397.76 g/molD-Ala-(19)-Semaglutide
<p>D-Ala(19)-Semaglutide is a semaglutide impurity. The amino acid at position 19 has been replaced by the D-form of the amino acid D-alanine (D-Ala). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molBortezomib intermediate I
CAS:<p>Bortezomib intermediate I is a metabolite of bortezomib, which is a research and development drug product. Bortezomib intermediate I is an impurity standard for bortezomib. Bortezomib intermediate I can be synthesized from the corresponding compound. It is an analytical standard used in pharmacopoeia and can be used as an API impurity or synthetic material in drug development. Bortezomib intermediate I has a high purity, natural origin, and a niche application. CAS No. 1248339-44-7</p>Fórmula:C25H36BN5O4Pureza:Min. 95%Forma y color:White PowderPeso molecular:481.4 g/molSemaglutide Impurity 51 (D-Thr 7)
<p>D-Thr(7)-Semaglutide is a semaglutide impurity. The amino acid at position 7 has been replaced by the D-form of the amino acid D-threonine (D-Thr). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molD-Ala(24)-Semaglutide
<p>D-Ala(24)-Semaglutide is a semaglutide impurity. The amino acid at position 24 has been replaced by the D-form of the amino acid D-alanine (D-Ala). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/mol
